[Surgical treatment of Crohn disease and ulcerative colitis in standardized conditions].
Crohn's disease and colitis ulcerosa are marked by a high periintestinal infection rate as well as catabolism with negative protein balance. To eliminate these factors the principle of withdrawing the intestinal function has been applied. Patients are put on a completely absorbable diet (2,500-3,500 kcal/d) using a thin duodenal (or jejunal) tube for 4-6 weeks. Depending on the initial condition, assistant or total parenteral nutrition is performed. - 203 patients with Crohn's disease (n = 154) or colitis ulcerosa (n = 49) underwent elective surgery from January 1st, 1978 to April 30th, 1985. Using the preparation of withdrawing the intestinal function 85.7% of the patients have had an uncomplicated postoperative course. Septic complications were found in 12.8%, non-septic in 1.5%. The rate of mortality was 1.0%. In the case of Crohn's disease complications occurred in 10.4%, mortality was 0.6%.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003093:Colitis, Ulcerative / Q000601:surgery*; D003424:Crohn Disease / Q000601:surgery*; D004338:Drug Combinations / Q000627:therapeutic use; D004750:Enteral Nutrition; D005260:Female; D005526:Food, Formulated; D006801:Humans; D007420:Intestine, Large / Q000601:surgery; D007421:Intestine, Small / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care / Q000379:methods; D011292:Premedication; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013530:Surgical Wound Infection / Q000517:prevention & control*; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000890:Anti-Infective Agents; D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole
Die chirurgische Behandlung des Morbus Crohn und der Colitis ulcerosa unter einheitlichen Bedingungen.